In 2018, the IPO granted a patent to Apex Laboratories Private Limited for “A NOVEL CREAM AND A PROCESS TO MANUFACTURE THE SAME”  bearing Indian Patent number 302376. The Controller had cited Sections 3(d) and 3(e) of the Act, among other grounds, as objections in the First Examination Report [office action]. However, the Controller held that the objections had been met in light of the enhancement of therapeutic efficacy and synergistic effect of the claimed invention being established by the Applicant in its response to the Report.

 

A patent was granted by the IPO to HEIDELBERG PHARMA GMBH, a German Company, for “METHODS FOR SYNTHESIZING AMATOXIN BUILDING BLOCK AND AMATOXINS” bearing Indian Patent number 310496. The Controller had cited Section 3(d) of the Act, among other objections in the First Examination Report [office action]. However, the Controller granted the patent in light of the submissions made by the Applicant in its response to the Examination Report in merely 9 days from the date of submission of the Reply to the Examination Report by the Applicant.

 

Another patent was granted by the IPO to HEIDELBERG PHARMA GMBH for “AMATOXIN CONJUGATES WITH IMPROVED LINKERS” bearing Indian Patent number 310961. The Controller had cited Sections 3(d), 3(e) and 3(i) of the Act, among other objections in the First Examination Report [office action]. However, the Controller granted the patent in light of the submissions made by the Applicant in its response to the Examination Report.

A patent was granted by the IPO to ADVERIO PHARMA GMBH, a German Company, for “METHOD FOR PRODUCING SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES”  bearing Indian Patent number 303187. The Controller had cited Sections 3(d) and 3(i) of the Act, among other objections in the First Examination Report [office action]. However, the Controller granted the patent in light of the submissions made by the Applicant in its response to the Examination Report.

 

PHARMACEUTICAL PATENTING IN INDIA - BREAKING MYTHS

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Please reload

Please reload

Please reload

Subscribe for Updates